Innovative Medicine — Amortization
Business Segments · AmortizationJohnson & Johnson Innovative Medicine — Amortization decreased by 25.0% to $600.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 14.3%, from $700.00M to $600.00M.
Analysis
StatementSegment
CategoryEfficiency
SignalContext dependent
VolatilityStable
First reportedQ4 2022
Last reportedQ3 2025
How to read this metric
Higher amortization often reflects significant past M&A activity or heavy investment in intellectual property, while a decrease may suggest a maturing portfolio of assets.
Detailed definition
This represents the periodic expense recognized for the systematic allocation of the cost of finite-lived intangible ass...
Peer comparison
Standard across the pharmaceutical industry where M&A-driven intangible asset accumulation is common.
Metric ID:
jnj_segment_innovative_medicine_amortizationHistorical Data
9 periods
| Q4 '22 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|
| Value | $700.00M | $700.00M | $700.00M | $700.00M | $700.00M | $700.00M | $600.00M | $800.00M | $600.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | -14.3% | +33.3% | -25.0% |
| YoY Change | — | — | — | — | +0.0% | +0.0% | -14.3% | +14.3% | -14.3% |
Range$600.00M – $800.00M
CAGR-7.4%
Avg YoY Growth-2.9%
Median YoY Growth+0.0%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's innovative medicine — amortization?
- Johnson & Johnson (JNJ) reported innovative medicine — amortization of $600.00M in Q3 2025.
- How has Johnson & Johnson's innovative medicine — amortization changed year-over-year?
- Johnson & Johnson's innovative medicine — amortization decreased by 14.3% year-over-year, from $700.00M to $600.00M.
- What does innovative medicine — amortization mean?
- The non-cash expense related to the gradual write-down of acquired intangible assets like patents.